WP1122 from BIORBYT LTD.
Search, find, compare suppliers for WP1122 products.
| Edit | |
|---|---|
| Product Name | WP1122 |
| Description | WP-1122(WP 1122) is a candidate drug to treat SARS-COV-2(COVID-19).2-DG completely prevented SARS-CoV-2 replication in Caco-2 cells. Glycolysis is a process by which cells convert glucose into energy and infected (host) cells are induced by viruses to dramatically increase their dependence on glycolysis. WP1122 is a prodrug of 2-DG whereby chemical elements are added to 2-DG to improve its delivery in vivo. MW: 248.23 |
| Size | 25 mg, 10 mg |
| Concentration | n/a |
| Applications | n/a |
| Other Names | n/a |
| Gene, Accession, CAS # | CAS: 1204310-73-5 |
| Catalog # | orb1472983 |
| Price | please inquire |
| Order / More Info | WP1122 from BIORBYT LTD. |
| Product Specific References | n/a |
BIORBYT LTD.
BIORBYT LTD.
7 Signet Court
Swann Road
Cambridge, CB5 8LA U.K.
P: +44 (0)1223 859 353
F: +44(0)1223 280 240
info@biorbyt.com
http://www.biorbyt.com
U.S. OFFICE
Biorbyt LLC
1100 Corporate Square Drive
Helix Center, Suite 221
St Louis, MO 63132
Email: info@biorbyt.com
Phone: +1 (415) 906-5211
Fax: +1 (415) 651-8558
Profile of BIORBYT LTD.
Return to Products